304684-77-3

Exo2 (304684-77-3) disrupts the Golgi apparatus and stimulates Golgi-ER fusion in mammalian cells.1 May be used to completely ablate the Golgi apparatus.1 Like brefeldin A (BFA), it inhibits anterograde transport and disrupts morphology of the trans-Golgi network (TGN) but unlike BFA, it does not induce tubulation and merging of the TGN and endosomal compartments.2? It perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network, in contrast to cholera toxin.1,2 Accelerates degradation of perilipin-2 proteins.3

Exo2 is a secretion inhibitor. Exo2 perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network. Exo2 blocks secretory cargo exit from the ER (endoplasmic reticulum) and disrupts the Golgi apparatus, but does not affect the morphology of the TGN (trans-Golgi network) Exo2 can stimulate calcium-dependent exocytosis in permeabilized adrenal chromaff in cells[1][2].

ChEBI: Exo2 is a member of phenols and a member of methoxybenzenes.

1) Feng et al. (2004), Retrograde transport of cholera toxin from the plasma membrane to the endoplasmic reticulum requires the trans-Golgi network but not the Golgi apparatus in Exo2-treated cells; EMBO Rep., 5 596 2) Spooner et al. (2008), The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network; Biochem. J., 414 471 3) Pauloin et al. (2016), The perilipin-2 (adipophilin) coat of cytosolic lipid droplets is regulated by an Arf1-dependent mechanism in the HC11 mouse mammary epithelial cells; Cell Biol. Int., 40 143